Combining the EndoBarrier Gastrointestinal Liner with a new EndoBarrier Flow Restrictor nearly doubling the amount of weight loss
The results were presented today at the 26th annual meeting of the American Society for Metabolic and Bariatric Surgery (ASMBS). The most common side effects included mild to moderate abdominal pain, nausea and vomiting. "These results are unparalleled for a non-surgical treatment for obesity," stated Alex Escalona, M.D., Department of Digestive Surgery, Pontificia Universidad Católica de Chile, Santiago, Chile and lead investigator for the pilot study.
"Like the United States, Chile is struggling with a growing epidemic of obesity and related metabolic disorders and life-threatening conditions. Traditionally, non-surgical treatment approaches have proven insufficient for the morbidly obese, but these data suggest we may have an effective new option to offer these patients.
Read more on: Medical News Today
0 comments:
Post a Comment